Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

被引：48
|
作者：
Sharma, Padmanee
Pachynski, Russell Kent
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matt D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit Kumar
Ciprotti, Marika
Duan, Tao
Saci, Abdel
Hu, Sarah
Han, G. Celine
Fizazi, Karim
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Ctr Leon Berard, Lyon, France
[5] Inst Paoli Calmettes, Med Oncol, Marseille, France
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[7] Ctr Jean Perrin, Clermont Ferrand, France
[8] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
    Schallier, D.
    Decoster, L.
    Braeckman, J.
    Fontaine, C.
    Degreve, J.
    ANTICANCER RESEARCH, 2012, 32 (02) : 633 - 641
  • [43] Ipilimumab A potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer
    Kittai, Adam
    Meshikhes, Mariam
    Aragon-Ching, Jeanny B.
    CANCER BIOLOGY & THERAPY, 2014, 15 (10) : 1299 - 1300
  • [44] Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
    McGregor, B. A.
    Campbell, M. T.
    Huang, J.
    Xie, W.
    Bilen, M. A.
    Mortazavi, A.
    Ravi, P.
    Shah, A.
    Einstein, D.
    Sonpavde, G. P.
    McKay, R. R.
    Siefker-Radtke, A. O.
    Bellmunt, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1206
  • [45] Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
    Lebbe, C.
    Meyer, N.
    Mortier, L.
    Marquez-Rodas, I.
    Robert, C.
    Rutkowski, P.
    Menzies, A. M.
    Eigentler, T.
    Ascierto, P. A.
    Smylie, M.
    Ajaz, M.
    Svane, I-M.
    Gonzalez, R.
    Rollin, L.
    Saci, A.
    Grigoryeva, E.
    Pigozzo, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 737 - 737
  • [46] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [47] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Slovin, S. F.
    Higano, C. S.
    Hamid, O.
    Tejwani, S.
    Harzstark, A.
    Alumkal, J. J.
    Scher, H. I.
    Chin, K.
    Gagnier, P.
    McHenry, M. B.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821
  • [48] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
    Drake, C. G.
    Saad, F.
    Clark, W. R.
    Ciprotti, M.
    Sharkey, B.
    Subudhi, S. K.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S546 - S546
  • [50] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
12345